Alphamab Oncology ( (HK:9966) ) has shared an update. Alphamab Oncology announced that its Investigational New Drug application for JSKN022, a novel bispecific antibody-drug conjugate targeting PD-L1 ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New ...

PASADENA, Calif.-- (BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...

Shares of Zymeworks were higher after the Food and Drug Administration cleared the company's investigational new drug application for its treatment for liver cancer. The stock rose 8.5%, to $14.46, in ...

New hope could be on the horizon for ALS patients in the form of a “breakthrough" drug, researchers say. Neuvivo is seeking approval for an experimental medication for the neurological condition.

Aldeyra Therapeutics, Inc., a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the ...

(RTTNews) - Spero Therapeutics, Inc. (SPRO), said on Monday that the U.S. Food and Drug Administration or FDA has granted priority review designation and confirmed a substantive review of the New ...

The application is supported by data from 2 randomized, open-label, multicenter phase 3 clinical studies (NCT04292730 and NCT04292899) conducted by Gilead and a randomized, placebo-controlled ...

U.S. FDA Accepts Supplemental New Drug Application (sNDA) and Grants Priority Review for NUBEQA® (darolutamide) in Combination with Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) ...